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Abstract 
Objective Flupirtine is a non-opioid analgesic with regulatory approval in a number of European 
countries.  Because of risk of serious liver injury, its use is now limited to short-term pain 
management. We sought to identify genetic risk factors for flupirtine-related drug-induced liver 
injury (DILI) as these are unknown. 
Materials and Methods Six flupirtine–related DILI patients from Germany were included in a 
genome-wide association study (GWAS) involving a further 614 European cases of DILI due to 
other drugs and 10588 population controls. DILI was diagnosed by causality assessment and expert 
review. HLA and SNP genotypes were imputed from the GWAS data, with direct HLA typing 
performed on selected cases to validate HLA predictions. Four replication cases which were 
unavailable for the GWAS were genotyped by direct HLA typing, giving an overall total of 10 
flupirtine DILI cases.  
Results In the six flupirtine DILI cases included in the GWAS, we found a significant enrichment of 
the DRB1*16:01-DQB1*05:02 haplotype compared to controls (minor allele frequency (MAF) 
cases 0.25 and MAF controls 0.013; p-value=1.4x10-5). We estimated an odds ratio for haplotype 
carriers of 18.7 (95% confidence interval (CI) 2.5-140.5, p-value=0.002) using population-specific 
HLA control data. The result was replicated in four additional cases, with a haplotype frequency of 
0.25 also. In the combined cohort (six GWAS plus four replication cases), the haplotype was also 
significant (odds ratio 18.7; 95%CI 4.31-81.42; p-value=6.7x10-5).  
Conclusion We identified a novel HLA class II association for DILI confirming the important 
contribution of HLA genotype to DILI risk generally. 
Keywords: Hepatotoxicity; Genome-Wide Association Study; Pharmacogenomics; Flupirtine; HLA 
allele, adverse drug reaction 
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Introduction 
Flupirtine is a non-opioid analgesic which appears to act as a selective neuronal potassium channel 
opening agent [1]. It was approved for use in Germany and Austria in 1984 and subsequently in a 
further 10 European Union countries but it has been used particularly widely in Germany [2, 3]. 
Flupirtine has been implicated in a number of cases of serious liver injury including those leading to 
acute liver failure and fatality reported through spontaneous adverse drug reaction (ADR) reporting 
in Germany [3]; in consequence of a review by European Medicines Agency’s Pharmacovigilance 
Risk Assessment Committee (PRAC), the drug is now recommended by German regulators for 
short-term use only in cases if other analgesics such as non-steroidal antiinflammatory drugs are 
contraindicated [4]. The precise incidence of liver injury in those treated with the drug remains 
slightly unclear with estimates ranging from 31% of patients exposed to at least 6 weeks of 
treatment in a clinical trial showing some elevation of liver enzymes [5] down to 0.8 in 10,000 
based on adverse drug reaction reportsin the German health authority (BfArM) database [3]. In a 
hospital-based case-control study from Berlin, flupirtine was the drug with the strongest association 
with acute DILI with an odds ratio of 40 (95% confidence interval (CI) 5.5-856.9) [6]. The liver 
injury pattern seen is predominantly hepatocellular and liver biopsies have shown perivenular 
necrosis with mild to moderate lymphocytic infiltration [2]. In addition, cases of acute liver failure 
and death from flupirtine have been included in the German spontaneous reporting system [4]. 
The metabolism of flupirtine is complex but does not involve the cytochromes P450 to any 
significant extent. The parent drug is subject to N-glucuronidation and may also be hydrolysed by 
esterases, followed by N-acetylation to form an active metabolite D13223 [7]. Flupirtine and 
D13223 are also oxidised by peroxidases, generating reactive quinone imines which can be 
conjugated with glutathione [7]. In a recent in vivo study, NAT2, UGT1A1 and GSTP1 genotype did 
not affect metabolic profile, but, some evidence was obtained that GSTP1 genotype for rs1695 and 
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the rarer rs1138272, which are both associated with amino acid changes, affected oral 
bioavailability [8]. 
To gain further insights into genetic factors affecting susceptibility to flupirtine-induced liver 
injury, we analysed six cases that were recruited as part of a larger multi-drug genome-wide 
association study (GWAS) on drug induced liver injury (DILI) due to a variety of different drugs. 
We report an association for flupirtine-related injury with a specific class II HLA haplotype and 
describe the confirmation and replication of this finding in four additional cases. 
Materials and Methods 
DILI cases 
Recruitment was performed as part of the larger International DILI Consortium (iDILIC) study. We 
recruited 11 individuals (10 female and 1 male, mean age at date of DILI 55 years) who were 
suspected of having suffered flupirtine-related DILI, but had recovered following drug withdrawal. 
The cases were identified by the German spontaneous reporting database. All participants gave 
written informed consent and the study was approved by the Ethics Committee of the Medical 
Faculty, University of Kiel. All cases provided a 10 ml blood sample for DNA preparation. Clinical 
data was collected from hospital or medical practice records. Only 10 cases who were classified on 
causality assessment as having at least possible flupiritine related DILI were included in the study 
[9]. Causality assessment was performed by application of the Council for International 
Organizations of Medical Science (CIOMS) scale, also called the Roussel Uclaf Causality 
Assessment Method (RUCAM) [10] and by an expert review from two hepatologists. The pattern of 
liver injury was classified according to the International Consensus Meeting Criteria [10]. The 
discovery portion of the analysis was a GWAS which utilized the six initially available flupirtine 
DILI cases together with an additional 614 DILI cases which had also passed expert adjudication 
but related to other drugs, with genotyping performed on the Illumina Infinium HumanCoreExome 
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BeadChip. Imputed HLA genotypes were later confirmed where possible by direct HLA typing. A 
further four flupirtine DILI cases became available later and were HLA-typed using a sequence-
based assay. These served as the replication cohort to confirm the HLA association for flupirtine-
related DILI identified in the discovery phase.  
European controls 
Since DILI has a very low prevalence, we used general population samples as study controls. The 
validity of this approach in studies on adverse drug reactions has been discussed in detail previously 
[11, 12]. We selected 10588 ethnicity-matched Caucasian controls from several available sources: 
the Welcome Trust Case Control Consortium (WTCCC) (http://www.wtccc.org.uk), POPulation 
REference Sample collection (POPRES) [11], the PGX40001 clinical study [13], the dbGAP study 
phs000346.v1 [14], the Hypergenes cohort (http://www.hypergenes.eu), the National Spanish DNA 
Bank cohort (http://www.bancoadn.org/), the Swedish Twin Registry cohort 
(http://ki.se/en/research/the-swedish-twin-registry) and the Italian Penicillin Tolerant Cohort 
(IPTC). Since the Hypergenes dataset contains only autonomic chromosomes, the sex chromosomes 
were not considered in the analysis. Information about the genotyping platform used by each of the 
control cohorts is reported in Table S1. The number of controls chosen was based on the power 
calculations reported in a previous study [12] but also to ensure appropriate ethnic matching for the 
entire DILI cohort of 620 cases who were recruited from a range of both Northern and Southern 
European countries. 
Quality checks for each genotyped cohort  
QC was conducted at both single marker and subject levels before performing the SNP imputation. 
Any marker that did not pass the following criteria was excluded from analysis: (i) genotype call 
rate in the batch of subjects greater than 95%, (ii) missing genotype rate greater than 5%, (ii) p-
value for Hardy-Weinberg equilibrium greater than 10-7 in controls (if applicable). Any subject that 
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did not pass the following criteria was excluded from analysis: (i) missing genotype rate < 0.05 
among the SNPs that passed QC; (ii) not a sample duplicate or closely related based on estimated 
identity-by-descent (IBD) using PLINK v 1.07. 
 
HLA genotyping 
DNA was prepared as described previously [15]. High resolution genotyping of HLA-A, B, C, 
DRB1, DQA1 and DQB1 was performed on all cases by Histogenetics (Ossining, New York). 
Sequencing data files were analyzed using Histogenetics’ proprietary analysis software for HLA 
genotype calling (Histomatcher and HistoMagic). Allele assignments are based on the IMGT/HLA 
Database release version 2.21.0, dated April 2008 (http://www.ebi.ac.uk/imgt/hla/). 
SNP Imputation 
For each control cohort, SNPs and samples with poor quality data were pruned before the 
imputation to avoid false positives (See Supplementary Material). The imputation was performed in 
batches dividing the cohorts according to genotyping platform. For each batch we first phased the 
data by SHAPEIT (version v2.r727), to increase the accuracy of the imputation [16]. Then, 
imputation was carried out using IMPUTE2 (version 3) [17] with data from the 1000 Genomes 
Project (release v3) [16] as the reference panel. We used an ethnic mixed panel to improve the 
quality of the imputation [18]. We retained imputed genotypes with: (a) posterior probability > 0.9 
in each genotyping batch, (b) no significant difference in missingness between cases and controls 
(χ2 test, p-value > 0.0001), (c) no significant deviation from Hardy-Weinberg equilibrium (p-value 
> 0.0001), (d) no missing data at a frequency greater than 5% in each single genotyping batch, (e) 
info score greater than 0.8 in each genotyping batch, (f) minor allele frequency (MAF) in the 1000 
Genomes Project greater or equal to 0.01. Batch effects for imputed SNPs were corrected by testing 
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for association between ethnically-matched controls typed by different platforms (using logistic 
regression). SNPs with association p-values less than 0.005 were excluded from the analysis.  
HLA imputation 
For each cohort, HLA alleles were inferred using HIBAG [19] using the reference predictor panels 
specific for the genotyping chip. 
Statistical analysis 
The effect of population structure was assessed through principal components analysis (PCA) using 
the smartPCA program from the EIGENSTRAT package (version 3.0) [20]. The statistical 
association of each genomic variant was determined by logistic regression using the first seven 
significant principal components as covariates under an additive model. Association analyses were 
carried out by PLINK 1.07 [21]. We set the GWAS genome-wide significance p-value threshold to 
5x10-8 to correct for multiple testing. In total, we imputed 217 HLA alleles in the overall European 
cohort. We set the MHC-region-wide significance p-value threshold for the HLA allele association 
to 2.3x10-4 to correct for multiple testing (Bonferroni correction).  Fisher's exact test was used to 
test the HLA association when data from the Allele Frequencies repository 
(http://www.allelefrequencies.net) was analyzed. The number of carriers was estimated based on 
the reported HLA allele frequency assuming Hardy-Weinberg equilibrium. The analyses were 
performed with R (Version 3.0.2) [22].  
Results 
Clinical characteristics of the cases 
A summary of the clinical characteristics is provided in Table 1. The six cases used in the discovery 
GWAS analysis were recruited first and passed adjudication with RUCAM scores of between 3 and 
8 (indicating a “possible” or “probable” causal relationship). For one of these cases the causal drug 
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was ambiguous, with identical RUCAM scores for flupirtine and diclofenac. For the other 5 cases 
flupirtine was found to be the sole cause of DILI. An additional 5 cases became available later. The 
RUCAM scores for these varied between 2 and 7. A single case showing a score of 2 was 
eliminated from the study, leaving 4 cases available for replication genotyping. 
GWAS findings and HLA allele assignment by imputation 
Principal component analysis confirmed the self-reported ethnicity for the cases and divided the 
controls into four major clusters (Figure S1). No genome-wide significant signal for flupirtine cases 
was detected in the GWAS (Figure S2). Findings for other cases have been described elsewhere 
[23]. Table 2 summarises the imputed DRB1 and DQB1 genotypes for all the flupirtine cases that 
passed adjudication. Three out of the six cases included in the GWAS were predicted to be 
heterozygous for two class II HLA alleles DRB1*16:01 and DQB1*05:02, showing higher allele 
frequency in cases (0.25) compared with controls (0.013 for DRB1*16:01 and 0.017 for 
DQB1*05:02). These two HLA alleles have a similar frequency in the controls and are in linkage 
disequilibrium (r2 = 0.8). Their combination forms a well-known haplotype observed in a range of 
populations worldwide (http://www.allelefrequencies.net). It was therefore probable that all three 
cases would be heterozygous for the HLA class II haplotype DRB1*16:01-DQB1*05:02, giving a 
frequency of 0.25 for the haplotype. Interestingly, the single DILI case (case 5) for which causal 
drug assignment was ambiguous was predicted to be negative for the haplotype.  
The odds ratio of the haplotype DRB1*16:01-DQB1*05:02 in cases versus controls was 45 (95% 
CI 8.0-251.3, p-value= 1.4x10-5). rs137931178 was the SNP with the lowest p value in the MHC 
region (OR = 79, 95%CI 11.72-533.7, p-value = 7.2x10-6) and correlated with these HLA alleles in 
the controls (r2 of 0.7 with DRB1*16:01). The frequency of the imputed haplotype DRB1*16:01-
DQB1*05:02 in 616 European non-flupirtine DILI cases from the iDILIC cohort was found to be 
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0.015, which was comparable with the frequency of this haplotype in the overall controls (0.013), 
suggesting that the apparent association is specific to flupirtine-related DILI.  
Haplotype frequency data are not available for any large general European or German cohorts but 
there are detailed data on individual allele frequencies available (http://www.allelefrequencies.net). 
The frequency of DRB1*16:01 in the largest European group (USA NMDP European Caucasian 
cohort, n=1,242,890 individuals) was 0.014 and confirmed our estimate of 0.013 for European 
controls. To further assess the significance of the candidate association with DRB1*16:01, we used 
population specific frequency data for DRB1*16:01 only in Germans (German pop 8, n=39,689) 
where DRB1*16:01 occurred at a frequency of 0.026. Based on carriage of the DRB1*16:01 allele, 
the population corrected OR for flupirtine DILI was 18.7 (95%CI 2.5-140.5; p-value=0.002).  
Confirmation of the imputed HLA genotypes and replication of the association 
We used sequence-based HLA typing to profile the four replication cases along with two of the six 
cases from the discovery GWAS phase. The imputed HLA genotypes were confirmed for two of the 
three GWAS cases predicted to carry DRB1*16:01-DQB1*05:02. No DNA from the third positive 
case and the cases predicted to be negative for DRB1*16:01 haplotype was available for the 
additional typing. As summarised in Table 2, two of the four replication cases were heterozygous 
for DRB1*16:01 and DQB1*05:02, giving an allele frequency of 0.25 for both alleles in line with 
the GWAS findings. This suggested an overall frequency of 0.25 for the haplotype among the 10 
confirmed DILI cases, with 50% of all cases heterozygous carriers of the risk haplotype. In the 
combined cohort, we estimated the German-specific odds ratio for carriage of DRB1*16:01 to be 
18.74 (95% CI 4.31 to 81.42). After correction for multiple comparisons for the entire MHC region, 
the association remained statistically significant (uncorrected p-value 6.7x10-5).  
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Genotypes for polymorphisms relevant to flupirtine metabolism 
NAT2, UGT1A1 and GSTP1 are involved in flupirtine metabolism [8] and these genes are also 
subject to common polymorphisms with well-established phenotypic effects. NAT2 (rs1801280, 
rs1799930, rs1799931) and GSTP1 (rs1695) genotypes relevant to phenotype were available from 
the GWAS data. Three cases (50% of the group) were predicted to be NAT2 slow acetylators with 
genotypes of *5/*6 (2 cases) and *5/*5 (1 case). The other three samples were fast acetylators with 
genotypes of *4/*5 (2 samples) and *4/*4 (1 sample). This frequency of NAT2 slow acetylators is 
not significantly different to that in Europeans generally which has been estimated to be 57% from 
genome sequencing [24]. Three cases were heterozygous for GSTP1 rs1695 with the other three 
homozygous wild-type for this allele. The frequency of this polymorphism in our Europeans 
controls (0.34) was higher than in cases (0.25), but it was not significantly different (OR=0.7, 
95%CI 0.2-2.7, p-value = 0.6).  For UGT1A1, genotype data for the well-characterised TA repeat 
polymorphism which can be used to predict the decreased UGT1A1 expression which gives rise to 
Gilbert's syndrome was not available in our cases. However, genotypes for rs4124874 which is a 
tag SNP for the most common haplotype associated with normal UGT1A1 activity [25] were 
available. We found that the frequency of this SNP in the cases was not significantly different to the 
controls (OR=0.64, 95%CI 0.18-2.24, p-value=0.49).  
Discussion 
We found an association of DRB1*16:01-DQB1*05:02 with flupirtine-related DILI, with carriers of 
this haplotype being at 19-fold higher risk of developing a clinically significant adverse drug 
reaction. The finding that HLA alleles confer elevated risk is consistent with previous reports on 
DILI due to a number of other drugs [26] as well as previous clinical and histological reports of 
immune-mediated toxicity with moderate lymphocytic infiltration and extensive perivenular 
necrosis seen on liver biopsy in some flupirtine DILI cases [2, 5]. This indicates that the increased 
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risk of DILI due to flupirtine in DRB1*16:01-DQB1*05:02 carriers is likely to involve an 
inappropriate T cell response within the liver. Both HLA class I and II associations with DILI due 
to other drugs have been reported previously, though the current study is the first report of an 
association with DRB1*16:01-DQB1*05:02. A class II haplotype which includes DRB1*15:01 has 
been shown to be associated with both co-amoxiclav and lumiracoxib DILI in previous studies [27, 
28]. There is homology between DRB1*15:01 and DRB1*16:01, with both being members of the 
DR2 serotype group. However, despite showing sequence homology, the alleles have distinct 
disease associations. For example, DRB1*15:01 is protective against type I diabetes but this 
protective effect does not extend to DRB1*16:01 [29] while DRB1*15:01 is a well-established 
susceptibility factor for multiple sclerosis but DRB1*16:01 is not a risk factor [30]. 
So far, HLA associations for DILI with a predominantly hepatocellular phenotype have been with 
class II but not class I alleles (e.g. lapatinib [31], ximelagatran [32], lumiracoxib [28]) and the new 
findings for flupirtine are in line with this. On the other hand, certain cholestatic/mixed reactions to 
single drugs such as flucloxacillin [33] and ticlopidine [34] involve HLA class I alleles. The risk of 
DILI involving the antimicrobial co-amoxiclav appears higher in individuals expressing particular 
HLA class I and/or class II alleles but this more complex association appears to involve 
inappropriate T cell responses to both drugs [35] and the phenotype, though most frequently 
cholestatic or mixed, is sometimes hepatocellular [36]. The underlying mechanism by which 
inappropriate T cell reactions are triggered in DILI reactions remains unclear but recent in vitro 
studies on T cell responses in DILI cases due to flucloxacillin and co-amoxiclav [35, 37] suggest a 
hapten mechanism is more likely than a direct interaction by the drug with the HLA protein of the 
type that appears to occur in abacavir hypersensitivity [38]. Further similar investigations on the 
mechanism involved in the apparently exclusively HLA class II-associated flupirtine DILI would be 
interesting. 
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Specific HLA alleles have been identified as strong risk factors for the development of adverse drug 
reactions in studies involving small numbers of cases but the current study appears have involved 
the smallest discovery cohort up to the present with only 6 cases. Some previous studies showing 
HLA associations with DILI involved only slightly larger numbers of cases, for example 22 cases 
for the ticlopidine DILI association with HLA-A*33:03 [34] and 35 cases in the original report of 
the association of HLA-DRB1*15:01 with co-amoxiclav DILI [39]. These associations were also 
with relatively rare HLA alleles. In the current study, the very low population frequency of the "at 
risk" haplotype combined with the relatively large effect size were important factors in our ability 
to detect a significant genetic association when only a small number of cases were available. The 
subsequent availability of replication cases was a further advantage. It remains possible that HLA 
associations relevant to other adverse drug reactions may be detectable when similarly small 
numbers of cases are available. 
No other genetic risk factors with high odds ratios were detected in the GWAS. The metabolic 
pathway of flupirtine is now well understood and it has been suggested that quinone imine 
intermediates could contribute to the liver toxicity [8]. In particular, it was suggested previously 
that the well-established polymorphisms in NAT2, UGT1A1 and GSTP1 could influence levels of 
toxic metabolites but a study in healthy volunteers failed to detect statistically significant 
differences in pharmacokinetics between the various genotype groups except for a small difference 
for GSTP1 [8]. Our study confirmed that the frequencies of relevant polymorphisms from the 
GWAS data were similar to those seen in European populations generally so these genotypes do not 
appear to be risk factors. However, in view of the small numbers of cases studied, the findings need 
to be treated with caution. 
It should be noted that only a very small proportion of the total risk of DILI will relate to the HLA 
genotype described in the current study, but factors such as age above 60 and female gender also 
appear to contribute to risk. The age and gender distribution of the cases in the current study 
 14 
together with the DILI phenotype are in agreement with previous reports on DILI due to other drugs 
[40]. Age over 60 years has been described as a risk factor for flucloxacillin DILI where there is 
also a strong association with HLA genotype [33]. Flupirtine DILI appears to manifest relatively 
early in the course of therapy with 31% of patients treated for at least 6 weeks showing ALT and/or 
AST elevation in excess of 3 fold above ULN [5]. Another study, however, reported elevated "liver 
enzymes/bilirubin" in 3 of 105 patients treated with the drug for 5 to 7 days [41]. In line with some 
patients showing toxicity after relatively short exposures, the mean length of exposure in the current 
study was 65 days but overall exposure length ranged from 15 to 180 days. However, this time was 
above the recommended maximum treatment period of 14 days [4] in all cases. 
In summary, we have demonstrated a strong association between flupirtine DILI and the 
DRB1*16:01-DQB1*05:02 haplotype adding further evidence to the involvement of the adaptive 
immune system in the pathogenesis of DILI.  
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Table 1 Clinical characteristics of the patients 
 
  
	 	 	 	 	 	 	 	 	 	
	 Number Study Phase Age/sex DILI phenotype RUCAM score Time on flupirtine prior DILI 
Exposure to other 
hepatotoxic drugs 
Peak ALT 
(units/l) 	
	 1 Discovery phase (GWAS) 57/F Hepatocellular 5 (possible) 180 No 2460 	
	 2 Discovery phase (GWAS) 49/F Hepatocellular 7 (probable) 43 No 800 	
	 3 Discovery phase (GWAS) 40/F Hepatocellular 3 (possible) 164 No 868 	
	 4 Discovery phase (GWAS) 70/F Hepatocellular 6 (probable) 30 No 725 	
	 5 Discovery phase (GWAS) 77/M Hepatocellular 8 (probable) 15 diclofenac 1856 	
	 6 Discovery phase (GWAS) 43/F Hepatocellular 7 (probable) 25 No 955 	
	 7 Replication phase  57/F Hepatocellular 4 (possible) 41 No 834 	
	 8 Replication phase  78/F Hepatocellular 4 (possible)  40 metamizole 591 	
	 9 Not included 29/F Hepatocellular 2 (unlikely) 92 oxycodon 477 	
	 10 Replication phase  52/F Hepatocellular 3 (possible) 20 No 2042 	
	 11 Replication phase  55/F Hepatocellular 7 (probable) 60 No 2190 	
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Table 2 HLA DRB1 and DQB1 genotypes in cases showing possible or higher causality 
        
Number Type of case Genotyping method DRB1 genotype DQB1 genotype 
 
 
1 GWAS Imputation and direct typing 11:04:01 16:01:01 03:01:01  05:02:01  
2 GWAS Imputation 01:01 03:01 02:01 05:01  
3 GWAS Imputation and direct typing 04:04:01 16:01:01 03:02:01 05:02:01  
4 GWAS Imputation 11:01 16:01 03:01 05:02  
5 GWAS Imputation 14:01 15:01 05:03 06:02  
6 GWAS Imputation 07:01 13:01 03:03 06:03  
7 Replication Direct typing 04:04:01 07:01:01G 02:01:01G 03:02:01G  
8 Replication Direct typing 07:01:01G 16:01:01 03:03:02 05:02:01  
10 Replication Direct typing 03:01:01G 04:08:01 02:01:01 03:04:01  
11 Replication Direct typing 04:01:01 16:01:01 03:01:01 05:02:01  
 
Where direct typing was performed, 6 digit genotypes are shown if available. Imputed genotypes were to 4 digits only 
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